ProKidney reported $51.8 million net loss before noncontrolling interest for the quarter ended September 30, 2026, with $141.9 million in cash, cash equivalents and marketable securities. PROACT 1 remains on track for an eGFR slope topline readout in Q2 2027.
PROK · Prokidney Corp.
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, substantial doubt exists about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued.”View the 10-Q filed Nov 12, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
ProKidney Corp. faces substantial going-concern doubt and expects existing cash, cash equivalents and marketable securities to fund operations into mid-2027. PROACT 1 Phase 3 surrogate-endpoint data are expected in the second quarter of 2027.
ProKidney expects enrollment to finish in Q1 2027 and an accelerated approval readout in Q2 of next year. Cash of $142 million at the end of September is expected to support operations through mid-2027 after the readout.
ProKidney Corp. expects Phase 3 PROACT 1 topline data in Q2 2027, with cash, cash equivalents and marketable securities of $141.9 million expected to fund operations into mid-2027.
ProKidney entered an Open Market Sale Agreement with Jefferies LLC allowing it to sell Class A common stock up to $200,000,000 in aggregate offering price. Sales depend on effectiveness of a Form S-3 shelf registration filed October 29, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Class A and Class B common stock outstanding | 302,371,200 | as of September 30, 2026 | — |
| Total equity-based compensation expense | $5.88M | the three months ended September 30, 2026 filing | — |
| Weighted average shares of Class A common stock outstanding, basic and diluted | 207,760,422 | the three months ended September 30, 2026 filing | — |
| Cash and cash equivalents and marketable securities | $141.9M | as of September 30, 2026 | — |
| Shares Outstanding | 302,381,712 | as of November 6, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PROK
this stock
Prokidney Corp.
|
$320.52M | -52.7% | +1075.0% | — | 8.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 19
ProKidney Corp. faces substantial going-concern doubt and expects existing cash, cash equivalents and marketable securities to fund operations into mid-2027. PROACT 1 Phase 3 surrogate-endpoint data are expected in the second quarter of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PROK | -7.8% | -25.9% | -42.7% | -18.2% | -52.7% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -2.4% | -19.6% | -37.1% | -12.9% | -57.7% |